Patents by Inventor Donna Montgomery

Donna Montgomery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070264278
    Abstract: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full-length S. aureus polypeptide. The full-length polypeptide is referred to herein as full-length penicillin-binding protein 4 (“PBP4”). A His-tagged derivative of SEQ ID NO: 1 was found to produce a protective immune response against S. aureus.
    Type: Application
    Filed: September 13, 2005
    Publication date: November 15, 2007
    Inventors: Annaliesa Anderson, Donna Montgomery
  • Publication number: 20070134263
    Abstract: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length S. aureus polypeptide. The full-length polypeptide is referred to herein as full-length “sai-1”. A His-tagged derivative of SEQ ID NO: 1 was found to produce a protective immune response against S. aureus.
    Type: Application
    Filed: February 14, 2005
    Publication date: June 14, 2007
    Inventors: Annaliesa Anderson, Donna Montgomery
  • Publication number: 20060177462
    Abstract: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1, uses of such polypeptides, and expression systems for producing such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length <i>S. aureus</i> polypeptide. The full-length polypeptide is referred to herein as full-length “ORF0657n”. Polypeptides containing the amino acid sequence of SEQ ID NO: 1 were found to produce a protective immune response against <i>S. aureus</i>.
    Type: Application
    Filed: July 22, 2004
    Publication date: August 10, 2006
    Inventors: Annaliesa Anderson, Kathrin Jansen, Rosemarie Kelly, Loren Schulz, Donna Montgomery, William McClements
  • Patent number: 6384018
    Abstract: Genes encoding Mycobacterium tuberculosis (M.tb) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. Immune antisera was produced against M.tb antigens. Specific T-cell responses were detected in spleen cells of vaccinated mice and the profile of cytokine secretion in response to antigen 85 was indicative of a Th1 type of helper T-cell response (i.e., high IL-2 and IFN-&ggr;). Protective efficacy of an M.tb DNA vaccine was demonstrated in mice after challenge with M.bovis BCG, as measured by a reduction in mycobacterial multiplication in the spleens and lungs of M.tb DNA-vaccinated mice compared to control DNA-vaccinated mice or primary infection in naive mice.
    Type: Grant
    Filed: January 22, 1998
    Date of Patent: May 7, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Jean Content, Kris Huygen, Margaret A. Liu, Donna Montgomery, Jeffrey Ulmer
  • Publication number: 20020032162
    Abstract: Genes encoding Mycobacterium tuberculosis (M.tb) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. Immune antisera was produced against M.tb antigens. Specific T-cell responses were detected in spleen cells of vaccinated mice and the profile of cytokine secretion in response to antigen 85 was indicative of a Th1 type of helper T-cell response (i.e., high IL-2 and IFN-&ggr;). Protective efficacy of an M.tb DNA vaccine was demonstrated in mice after challenge with M.bovis BCG, as measured by a reduction in mycobacterial multiplication in the spleens and lungs of M.tb DNA-vaccinated mice compared to control DNA-vaccinated mice or primary infection in naive mice.
    Type: Application
    Filed: January 22, 1998
    Publication date: March 14, 2002
    Inventors: JEAN CONTENT, KRIS HUYGEN, MARGARET A. LIU, DONNA MONTGOMERY, JEFFREY ULMER
  • Patent number: 5736524
    Abstract: Genes encoding Mycobacterium tuberculosis (M.tb) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. Immune antisera was produced against M.tb antigens. Specific T-cell responses were detected in spleen cells of vaccinated mice and the profile of cytokine secretion in response to antigen 85 was indicative of a T.sub.h 1 type of helper T-cell response (i.e., high IL-2 and IFN-.gamma.). Protective efficacy of an M.tb DNA vaccine was demonstrated in mice after challenge with M. bovis BCG, as measured by a reduction in mycobacterial multiplication in the spleens and lungs of M.tb DNA-vaccinated mice compared to control DNA-vaccinated mice or primary infection in naive mice.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: April 7, 1998
    Assignees: Merck & Co.,. Inc., N. V. Innogenetics S.A.
    Inventors: Jean Content, Kris Huygen, Margaret A. Liu, Donna Montgomery, Jeffrey Ulmer